Literature DB >> 15234670

Cellular immune response of patients with neurocysticercosis (inflammatory and non-inflammatory phases).

Ednéia Casagranda Bueno1, Luís dos Ramos Machado, José Antônio Livramento, Adelaide José Vaz.   

Abstract

The cellular immune response in neurocysticercosis (NC) was studied in 22 patients, 11 (50%) of them in the inflammatory phase of the disease, by means of immunophenotyping of cells in cerebrospinal fluid (CSF) and peripheral blood (PB), lymphoproliferation assay with Taenia solium total saline extract (Tso) and Taenia crassiceps vesicular fluid (Tcra) as stimuli, and by determining the cytokine production profile in the cell culture supernatant. A higher mean percentage of CD19+ and CD56+ cells was observed in the CSF samples from inflammatory (16.8 and 11.3%) and non-inflammatory NC-patients (14.1 and 8.4%) when compared with the control group (CG, 7.6 and 5.4%). The CSF samples from inflammatory NC-patients also showed a higher percentage of HCAM (19.1%) and ICAM (44.9%) adhesion molecules when compared to CG (3.1 and 4.8%). The inflammatory phase showed predominance of CD8+ cells (CSF 26.6% and PB 36.2%) when compared with non-inflammatory phase (CSF 21.5% and PB 29.0%). All cell populations identified in the CSF from NC-patients showed cell activation (CD69+). The cell populations identified in PB showed higher expression of CD69 during the inflammatory phase, while only CD4+ cells presented no cell activation during the non-inflammatory phase. The antigen-specific lymphoproliferation assay showed mean positive results (stimulation index, SI > or = 2.5) only for cells from inflammatory NC-patients (Tcra 3.2 and Tso 5.4), but less intense than the CG (Tcra 5.7 and Tso 8.9). The cytokine production profile when using Tso antigen as stimuli showed differences between NC-patients with inflammatory (production of IL-4/IL-12/TNF-alpha/ICAM/VCAM) and non-inflammatory phase (production of IL-6/IL-10/IL-12/TNF-alpha/ICAM/VCAM). A prevalence of Th2 profile was observed in nine (69%) of the 13 (62% of total) NC-patients presenting positive SI. Cells from inflammatory NC-patients showed a predominance of a Th1 response upon in vitro stimulation, while those from non-inflammatory NC-patients showed a mixed Th1/Th2 pattern.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234670     DOI: 10.1016/j.actatropica.2004.05.010

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  6 in total

1.  Neurocysticercosis: local and systemic immune-inflammatory features related to severity.

Authors:  Brenda Sáenz; Agnes Fleury; Anahí Chavarría; Marisela Hernández; José C Crispin; María I Vargas-Rojas; Gladis Fragoso; Edda Sciutto
Journal:  Med Microbiol Immunol       Date:  2011-06-23       Impact factor: 3.402

2.  Immune-inflammatory markers in massively disseminated cysticercosis.

Authors:  Akhila Kumar Panda; Binod Kumar Pati
Journal:  BMJ Case Rep       Date:  2014-04-09

Review 3.  Corticosteroid use in neurocysticercosis.

Authors:  Theodore E Nash; Siddhartha Mahanty; Hector H Garcia
Journal:  Expert Rev Neurother       Date:  2011-08       Impact factor: 4.618

Review 4.  Immunology of Taenia solium taeniasis and human cysticercosis.

Authors:  H H Garcia; S Rodriguez; J S Friedland
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

5.  A Comparative Study of Peripheral Immune Responses to Taenia solium in Individuals with Parenchymal and Subarachnoid Neurocysticercosis.

Authors:  Iskra Tuero; Sandra Palma; Franco Cabeza; Sarah Saleemi; Silvia Rodriguez; Isidro Gonzales; Holger Mayta; Siddhartha Mahanty; Hector H Garcia; Robert H Gilman
Journal:  PLoS Negl Trop Dis       Date:  2015-10-27

6.  TNF-α blockade suppresses pericystic inflammation following anthelmintic treatment in porcine neurocysticercosis.

Authors:  Siddhartha Mahanty; Miguel A Orrego; Carla Cangalaya; M Paz Adrianzen; Gianfranco Arroyo; Juan Calcina; Armando E Gonzalez; Héctor H García; Cristina Guerra-Giraldez; Theodore E Nash
Journal:  PLoS Negl Trop Dis       Date:  2017-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.